US 12,448,450 B2
Method for treating tumor using anti-CTLA4 single-domain antibodies
Ting Xu, Suzhou (CN); Kangping Guo, Suzhou (CN); Xiaoxiao Wang, Suzhou (CN); Pilin Wang, Suzhou (CN); Yuhao Jin, Suzhou (CN); and Qian Li, Suzhou (CN)
Assigned to JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD., Jiangsu (CN)
Appl. No. 17/624,795
Filed by JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD., Jiangsu (CN)
PCT Filed Jul. 3, 2020, PCT No. PCT/CN2020/100232
§ 371(c)(1), (2) Date Jan. 4, 2022,
PCT Pub. No. WO2021/000953, PCT Pub. Date Jan. 7, 2021.
Claims priority of application No. PCT/CN2019/094751 (WO), filed on Jul. 4, 2019.
Prior Publication US 2022/0251207 A1, Aug. 11, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); C07K 2317/52 (2013.01); C07K 2317/567 (2013.01)] 10 Claims
 
1. A method of treating a tumor, wherein the method comprises administering a CTLA4-binding protein to a subject in need thereof,
wherein the CTLA4-binding protein comprises an antibody Fc domain and an antibody heavy chain variable region, and the antibody heavy chain variable region is directly or indirectly fused with the antibody Fc domain; and
wherein the heavy chain variable region comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 8 and 17-20, and the antibody Fc domain is of human IgG1 isotype subtype.